(Rule 14a-101)





Filed by the Registrant  

Filed by a Party other than the Registrant  


Check the appropriate box:


Preliminary Proxy Statement


Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))


Definitive Proxy Statement


Definitive Additional Materials


Soliciting Material under §240.14a-12

Evoke Pharma, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):


No fee required.


Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.




Title of each class of securities to which transaction applies:





Aggregate number of securities to which transaction applies:





Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):




Proposed maximum aggregate value of transaction:




Total fee paid:



Fee paid previously with preliminary materials.


Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.




Amount Previously Paid:




Form, Schedule or Registration Statement No.:





Filing Party:




Date Filed:







Evoke pharma Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meetingto be held on April 26, 2018, for Evoke Pharma, Inc.This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. Weencourage you to access and review all of the important information contained in the proxy materials before voting. To view theproxy statement and annual report, go to www.proxydocs.com/evok. To submit your proxy while visiting this site, you will needthe 12 digit control number in the box below.Under new United States Securities and ExchangeCommission rules, proxy materials do not haveto be delivered in paper. Proxy materials canbe distributed by making them available on theInternet. We have chosen to use these proceduresfor our 2018 Annual Meeting and need YOURparticipation.If you want to receive a paper or e-mail copy ofthe proxy materials, you must request one. Thereis no charge to you for requesting a copy. In orderto receive a paper package in time for this year’sannual meeting, please make this request on orbefore April 13, 2018.Printed materials may be requested by one of the following methods:INTERNETwww.investorelections.com/evokYou must use the 12 digit control numberlocated in the shaded gray box below.TELEPHONE(866) 648-8133*E-MAILpaper@investorelections.com* If requesting material by e-mail, please senda blank e-mail with the 12 digit control number(located below) in the subject line. No otherrequests, instructions or other inquiries should beincluded with your e-mail requesting material.ACCOUNT NO. SHARESThe purpose of the Annual Meeting is to take action on the following proposals:The Board of Directors recommends that you vote “FOR” the following.1. Election of two directors for a three-year term to expire at the 2021 annual meeting of stockholdersNominees 01 Cam L. Garner; and02 Scott L. Glenn2. Ratification of the appointment of BDO USA, LLP as our independent Registered public accountants for the year ending December 31, 20183. Approval of the Amendment and Restatement of 2013 Equity Incentive Award Plan4. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.Date: Thursday, April 26, 2018Time: 8:30 a.m. (Local Time)Place: 12670 High Bluff Drive, San Diego, CA 92130Evoke pharma Company Notice of Annual MeetingProxy Materials Available to View or Receive:1. Proxy Statement 2. Annual ReportFor a Convenient Way to View Proxy Materials_ and _VOTE Online go to: www.proxydocs.com/evok